Outlook Therapeutics (NASDAQ:OTLK) Inc ended its fiscal second quarter with $58.4 million in cash – enough to launch its lead drug ONS-5010 without raising significant additional capital, it said. ONS-5010, which will be sold under the brand name Lytenava, is an investigational ophthalmic formulation of bevacizumab u
Full Story >>
Vote
+15